32 results about "Epileptogenesis" patented technology

Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and epileptogenesis. Methods for preparing the compounds of the invention are also described.

Methods of treating or preventing an amyloid-related disease in a subject by administering to a subject a therapeutic amount of a compound of the invention are described. Also included are methods for inhibiting epileptogenesis in a subject, by administering to a subject an effective amount of an anti-epileptogenic agent. Methods for treating a subject suffering from an epileptogenesis-associated condition, by administering to the subject an effective amount of an anti-epileptogenic agent are also included. Methods for treating convulsions in a subject by administering to the subject an effective amount of a therapeutic amount of a compound of the invention are also described.

Neuronal excitation and inhibition of the brain is tracked in the hippocampal CA1 network during a latent period, wherein biomarkers are observed which include a sustained increase in the firing rate of the excitatory postsynaptic field activity, paired with a subsequent decrease in the firing rate of the inhibitory postsynaptic field activity; the mean amplitude profiles of both fEPSP and fEPSP field potential activity during the latent period have characteristic shapes; both excitatory and inhibitory CA1 field activity firing rates are observed to follow a circadian rhythm that drifts during epileptogenesis; the circadian rhythms described are in-phase in controls and anti-phase during epileptogenesis; and the fEPSP rate drifts from a circadian rhythm to a greater extent than the fEPSP rate. An additional biomarker is a change in a circadian rhythm of core body temperature. Therapeutic measures can include thermal, chemical, or electrical modulation, in an open or closed loop process.

Methods and compounds, such as beta-heterocyclic-beta-amino acids, useful for the inhibition of epileptogenesis are disclosed. Methods for preparing and using the beta-heterocyclic-beta-amino acids of the invention are also described.

The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to methods for the use of benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein to therapeutically or prophylactically treat, prevent, reverse, arrest or inhibit epileptogenesis and epilepsy.

This invention is directed to methods for preventing, treating, reversing, inhibiting or arresting epilepsy and epileptogenesis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

A method for identifying, suppressing, and reversing epileptogenesis, which is considered to be a learned response due to brain plasticity. The method includes identifying three epileptogenic conditions, neuronal hyperexcitability, spatial overconnectivity, and temporal overconnectivity. A treatment that accounts for each of these conditions is then be administered to the subject to reverse, or “unlearn,” epilepsy.

A method for identifying, suppressing, and reversing epileptogenesis, which is considered to be a learned response due to brain plasticity. The method includes identifying three epileptogenic conditions, neuronal hyperexcitability, spatial overconnectivity, and temporal overconnectivity. A treatment that accounts for each of these conditions is then be administered to the subject to reverse, or “unlearn,” epilepsy.

The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to methods for the use of benzo-heteroaryl sulfamide derivatives of formula (I) as described herein to therapeutically or prophylactically treat, prevent, reverse, arrest or inhibit epileptogenesis and epilepsy.

This invention is directed to methods for preventing, treating, reversing, inhibiting, or arresting epileptogenesis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof,: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

The present invention is related with the use of vinpocetine and the derivates developed from its formula that maintains the same effects for the treatment of epilepsy and its complications. Our results show that vinpocetine prevents all the abnormalities of the ABR waves that accompany the epileptic cortical activity observed for the ictal and post-ictal periods in two experimental models of epilepsy in vivo, that vinpocetine also inhibits the marked hearing loss and the characteristic EEG changes induced by two convulsing agents that differ in their mechanisms of action. These findings also indicate that the capacity of vinpocetine as an antiepileptic drug is not accompanied by adverse secondary effects.

The invention discloses an application of NMDA receptor NR2A subunit for selecting anti-epilepsy latent material and the application of antagonist, inhibitor or antagonist of NMDA receptor NR2A subunit for preparing the drug to treat epilepsy. The invention provides that the NR2A subunit of NMDA receptor is the subunit participating epilepsy generation or development, thereby providing a drug target for preventing or treating epilepsy.

This invention is directed to methods for preventing, treating, reversing, inhibiting or arresting epilepsy and epileptogenesis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof:wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and epileptogenesis. Methods for preparing the compounds of the invention are also described.

The present invention relates to compositions and methods for the treatment of epilepsy and related disorders. More specifically, the present invention relates to novel combinatorial therapies of epilepsy and related disorders.

The present invention relates to the application of a specific inhibitor for an SHH signaling pathway. Disclosed for the first time are that the SHH signaling pathway and excitability of neural networks have a close relationship and are involved in the formation and development of epilepsy, and are thus able to act as drug targets for developing drugs for improving or treating epilepsy. Also disclosed is a specific inhibitor for SHH signaling pathway capable of delaying epileptogenesis and being used as a drug for improving or treating epilepsy.

The present invention is directed to novel treatment of controlling hippocampal neural circuit hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comprising the step of contacting the hippocampus in said subject with a compound effective to restore excitatory / inhibitor balance thereby controlling the neural circuit hyperexcitability. Further provided is a method of treating a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comprising the step of administering an amount of an adenosine A1 receptor agonist pharmacologically effective to block epileptogenetic activities without blocking excitatory synaptic transmission.

The invention relates to application of a medicine taking alpha-asarone as a unique pharmacological active component in treatment of cerebral arterial thrombosis. The medicine provided by the invention can be used for effectively treating cerebral arterial thrombosis and has no obvious toxic or side effect. The medicine can obviously increase the blood flow ratio of the infarct side half brain to the opposite side half brain of a middle cerebral artery occlusion ischemia reperfusion rat and reduce the cerebral infarction volume; the nerve function score is obviously improved, and the lifetime of the model rat is prolonged; the occurrence rate of epilepsy caused by cerebral arterial thrombosis is obviously reduced.

The present invention relates to compounds and compositions useful for reducing the risk of epileptic occurrences and / or for alleviating epileptic phenomena in patients. In accordance with the invention, the compounds and compositions have at least the following two components: a) vitamin B6-based component selected from pyridoxal, pyridoxamine, pyridoxine, their pharmaceutically acceptable functional derivatives and salts; and b) at least one antiepileptic drug (AED) or anticonvulsive, neuro-protective drug or nootrope compound or moiety. The invention further relates to methods for preventing epileptic episodes and for alleviating epileptic episodes, as well as methods for reducing side effects of antiepileptic drugs.

Methods of anti-epileptogenesis treatment in which adenosine kinase (ADK) activity or expression is inhibited only transiently to provide a long-term benefit to a non-epileptic or epileptic subject. In an exemplary method, a therapeutically effective amount of an ADK inhibitor may be administered to a human non-epileptic subject over a finite, predetermined treatment period having a duration of less than two months. The non-epileptic subject may have sustained a precipitating event with a known risk to trigger latent development of an acquired form of epilepsy. Administration of the ADK inhibitor to the subject may be stopped at the end of the treatment period for at least the longer of (i) six months and (ii) ten times the duration of the treatment period. The step of administering may reduce the chance of the subject having seizures caused by the acquired form of epilepsy for an extended period following the end of the treatment period.

The present invention is directed to novel treatment of controlling hippocampal neural circuit hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comprising the step of contacting the hippocampus in said subject with a compound effective to restore excitatory / inhibitor balance thereby controlling the neural circuit hyperexcitability. Further provided is a method of treating a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comprising the step of administering an amount of an adenosine A1 receptor agonist pharmacologically effective to block epileptogenetic activities without blocking excitatory synaptic transmission.

Methods, systems, and apparatus for identifying biomarkers of epileptogenesis. The repository and analytics system includes multiple data source devices. The multiple data source devices are configured to provide neurological data. The repository and analytics system includes a repository and analytics platform that is coupled to the multiple source devices. The repository and analytics platform is configured to determine a relationship or pattern within the neurological data based on a linked set of neurological data. The repository and analytics platform is configured generate a visualization that identifies biomarkers of epileptogenesis based on the relationship or pattern. The repository and analytics system includes a client device. The client device is configured to display the visualization.

The invention provides an automatic quantitative analysis method for epileptic model electrophysiological signals, which comprises the following steps of: taking a characteristic value of data of epileptic model neural electrophysiological records as the input of a neural network, and taking a first interval number N and a first interval duration T obtained by a sliding window and a binning algorithm as the output of the neural network; calculating the number and duration of epilepsy through a neural network algorithm to replace manual judgment. According to the method, the electrophysiological signals of the epilepsy model can be evaluated quickly and accurately, the evaluation result is basically consistent with the result of manual evaluation, and quick and accurate efficacy evaluationcan be provided for high-throughput anti-epileptic drug screening.

The invention discloses applications of xenon or a xenon gas mixture in preparing preparations for treating epilepsy. Specifically, the invention relates to the following applications of xenon, wherein epilepsy is caused by paradoxical discharge of neurons, xenon can inhibit paradoxical discharge of the neurons and enhance the autophagy function of cells, and thus the inhibiting effect for occurrence and development of epilepsy is realized. According to the technical scheme, the fact that xenon or the xenon gas mixture has the obvious treatment and nerve protection effects for epilepsy is found for the first time, the difficulties including the drug tolerance generated by oral administration of medicines for treating epilepsy and the uncertainty caused by surgical treatment for epilepsy are overcome, meanwhile, the safety for xenon is proved in the application as an anesthetic, and therefore, a novel thought and a novel treatment medicine are provided for the treatment for epilepsy.

The invention discloses application of a ferroptosis-based key marker in high-throughput screening of an anti-epileptic regulating agent. The ferrous ions are used as the marker and can be used for preparing drugs, reagents or tools for screening anti-epileptic regulators, such as a near-infrared fluorescent probe FeP for detecting the ferrous ions. The near-infrared excitation two-photon fluorescent probe FeP is utilized to directly image the change of Fe < 2 + > in the brain of an epilepsy mouse living body, high spatial and temporal resolution is achieved, the dynamic change of Fe < 2 + > flux in the epilepsy generation and treatment process can be directly observed by utilizing the in-vivo three-dimensional dynamic two-photon imaging of FeP, a high-throughput screening platform combining FeP and high content analysis is constructed, it is found that a series of anti-epileptic compounds and the like can effectively regulate and control cell iron balance, it is proved that the anti-epileptic compounds have the remarkable anti-epileptic effect through behavior research and electroencephalogram monitoring analysis of an epileptic mouse model, and help is provided for screening drugs for treating epilepsy.

Methods and compounds useful for inhibiting convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent seizure onset and / or epileptogenesis. The present invention also describes processes for the preparation of the compounds of the invention.

The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to uses of benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein for the manufacture of a medicament to therapeutically or prophylactically treat, prevnet, reverse, arrest or inhibit epileptogenesis and epilepsy.

The invention relates to a traditional Chinese medicine pill for treating end-stage traumatic epilepsy, and belongs to the technical field of manufacturing of traditional Chinese medicine pills. The traditional Chinese medicine pill is prepared from the following raw materials in parts by weight: 10-40 parts of leeches, 10-18 parts of lumbricus, 10-18 parts of radix angelicae sinensis, 10-18 partsof peach seeds, 10-18 parts of rhizoma gastrodiae, 10-15 parts of radix curcumae, 10-18 parts of arisaema cum bile, 10-18 parts of bombyx batryticatus, 10-15 parts of radix codonopsis, 20-50 parts ofliquorice root, 10-30 parts of ruddle, 10-18 parts of rhizoma dioscoreae, 10-18 parts of rhizoma alismatis, 10-18 parts of radix salviae miltiorrhizae, 10-30 parts of rhizoma chuanxiong and 10-18 parts of poria cocos. The drug has the efficacy of invigorating the circulation of blood to dispel blood stasis and stimulating the menstrual flow, clearing away the heat to reduce phlegm, promoting qi to activate blood, obviously improving impetus of blood vessel of brain and paradoxical discharge of cerebral cortex, and relieving convulsion, calming down epilepsy and resisting convulsion, and can rapidly relieve and eliminate the instant symptoms of a patient, the side effect is less, the drug application time is short, the treatment effect is superior to pure western drug therapy, the drug canimprove prognosis and prevent intractable epilepsy from occurring, the recovery rate is high, and recurring is not liable to happen.